CD137 agonist induces gastric cancer cell apoptosis by enhancing the functions of CD8\(^+\) T cells via NF-κB signaling

Ben-Shun Hu\(^1,2\), Tian Tang\(^1\), Jun-Li Jia\(^1\), Bi-Chen Xie\(^3\), Tie-Long Wu\(^4\), Ying-Yue Sheng\(^4\), Yu-Zheng Xue\(^4\)* and Hua-Min Tang\(^1\)*

**Open Access**

**Background**: CD137 is a target for tumor immunotherapy. However, the role of CD137 in gastric cancer (GC), especially in inducing GC cell apoptosis, has not been studied.

**Methods**: Foxp3\(^+\) and CD8\(^+\) T cells in GCs were investigated using immunohistochemistry (IHC). CD137 expression in GCs was detected using flow cytometry, IHC and immunofluorescence (IF). Peripheral blood mononuclear cells (PBMCs) and CD8\(^+\) T cells isolated from peripheral blood were stimulated with a CD137 agonist in vitro. CD8\(^+\) T cell proliferation and p65 expression was examined using flow cytometry. P65 nuclear translocation was analyzed using IF. IL-10, TGF-β, IFN-γ, perforin and granzyme B were detected using real-time quantitative PCR (real-time PCR). PBMCs and primary GC cells were cocultured and stimulated with a CD137 agonist in vitro. Apoptosis of primary GC cells was detected using flow cytometry.

**Results**: Our data demonstrated that GC tumors showed characteristics of an immunosuppressive microenvironment. CD137 was predominantly expressed in CD8\(^+\) T cells in GCs and had a positive correlation with tumor cell differentiation. The CD137 agonist promoted CD8\(^+\) T cell proliferation and increased the secretion of IFN-γ, perforin and granzyme B, which induced primary GC cell apoptosis. Mechanistically, this study found that the CD137 agonist induced NF-κB nuclear translocation in CD8\(^+\) T cells.

**Conclusion**: Our results demonstrated that a CD137 agonist induced primary GC cell apoptosis by enhancing CD8\(^+\) T cells via activation of NF-κB signaling.

**Keywords**: CD137, Gastric cancer, CD8\(^+\) T cells, Immune microenvironment, Immune checkpoint

---

**Background**

Gastric cancer (GC) is a common malignant tumor. Chemotherapy and molecular-targeted therapy achieved limited improvements in survival \([1, 2]\). Immunotherapy is a new method of tumor treatment in addition to surgery, chemotherapy and radiotherapy \([3, 4]\). Therapeutic vaccines activate the initial T lymphocyte reaction, and enhances the activity of T lymphocytes \([5]\). Adaptive immunotherapy achieved an antitumor effect via the reinfusion of tumor-specific effector lymphocytes expanded in vitro \([6]\). Immunosuppressive agents showed a certain effect in the
treatment of GC, but immune checkpoint agonists are less studied in GC.

CD137, also known as 4-1BB, is a member of the tumor necrosis factor (TNF) receptor family, and it is encoded by the TNF receptor superfamily member 9 (TNFRSF9) gene [7, 8]. Mouse CD137 is located at 75.5 cm on mouse chromosome 4, and it exhibits approximately 60% homology with human CD137 [9]. CD137 is primarily expressed in activated CD8+ and CD4+ T cells and regulatory T cells (Tregs) [10, 11]. Accumulated animal experiments demonstrated that mice with a systemic deletion of CD137 genes showed disordered immune homeostasis and lost the ability to fight against tumor immune memory. However, the role of CD137 in GC was not investigated [12].

CD137 expression is upregulated on antigen-presenting cells (APCs) as a result of the activation of T cells initiated by B7-1, B7-2 and antigenic peptides, which promote the production and secretion of cytokines via the activation of NF-κB [13, 14]. It is well established that CD137 induces TNFR-related factors TRAF1 and TRAF2 to form a heterotrimer, which activates mitogen-activated protein kinase (MAPK), β-catenin and AKT signaling and augments NF-κB nuclear translocation [15–17]. Notably, the activation of NF-κB contributes to the survival of CD8+ T lymphocytes by increasing the expression of the antiapoptotic genes Bcl-xL and bfl-1 [11, 18]. However, whether CD137-mediated activation of NF-κB in CD8+ T lymphocytes induces GC cell apoptosis by enhancing the function of CD8+ T cells is not clear.

The most effective approach for CD137 agonist therapy is stimulation of the proliferation of CD8+ T cells by increasing the expression of IFN-γ and several granzymes [19]. The CD137 costimulatory signal is activated by a CD137 agonist or CD137L transfection, which induces cell proliferation, cytokine expression and bactericidal activity and supports T cell effector function [20]. CD137 agonists also inhibit the differentiation of conventional effector cells into Tregs, negatively regulates the activity of Tregs, or maintains the expansion and inhibition of Tregs [21]. However, the role of CD137 in Tregs of GC patients has not been investigated.

The present study demonstrated that GC tumors showed the characteristics of an immunosuppressive microenvironment. A CD137 agonist induced primary GC cell apoptosis by enhancing CD8+ T cells via activation of NF-κB signaling and increased the secretion of IFN-γ, perforin and granzyme B, but had little effect on Tregs in GC.

Materials and methods

Patients and specimens
For phenotypic assays, 23 fresh paired gastric cancerous, tumor margin and tumor-free gastric tissues (greater than 1-cm distance from the tumor), routinely paraffin-embedded for immunohistochemistry (IHC) and immunofluorescence (IF), were collected from 23 patients with GC who underwent surgery at our hospital between May 2019 and July 2020. Tumor infiltrating lymphocytes (TILs) isolated from above 23 fresh gastric cancerous tissues for flow cytometry, were collected. The clinical characteristics of the patients for phenotypic assay are listed in Table 1.

For functional assays, peripheral blood from 18 patients with GC was collected before surgery. Paired 18 fresh gastric cancerous tissues were collected during surgery. The clinical characteristics of the patients for functional assays are listed in Table 2.

None of the patients who provided samples received preoperative radiotherapy or chemotherapy and were confirmed to have GC on postoperative pathology. The

| Table 1 Characteristics of patients for phenotypic data |
|-------------------------------------------------------|
| **Sex** | **GC(23)** |
| Female | 14 |
| Male | 9 |
| Age (years)** | 58.2 ± 3.6 |
| Tumor size (cm) | |
| < 5 | 15 |
| ≥ 5 | 8 |
| Smoking | |
| Yes | 17 |
| No | 6 |
| Drinking alcohol | |
| Yes | 12 |
| No | 11 |
| Tumor location | |
| Proxima | 16 |
| Distal | 7 |
| Histopathology | |
| Highly differentiated adenocarcinoma of GC | 6 |
| Poorly differentiated adenocarcinoma of GC | 17 |
| Lymph node metastasis | |
| N0–1 | 19 |
| N2–3 | 4 |

**GC** gastric cancer

**Mean ± SD**
present study was performed in accordance with ethical standards and according to the declaration of the national and international guidelines. All the assays performed involving human peripheral blood and tissue samples (fresh gastric cancerous, tumor margin, and tumor-free gastric tissues) were approved by the Ethics Committee of Jiangnan University (No. LS2018021). All participants were aware of the study and signed an informed consent for publication.

**Antibodies and reagents**

RNAlater® was purchased from Ambion, USA. TRIzol was purchased from Invitrogen, USA. DEPC was purchased from Bio Basic Inc, Canada. The SYBR® PrimeScript® RT-PCR Kit was purchased from TaKaRa, Japan for two-step RT-PCR. PCR primers were designed by TaKaRa, Japan and synthesized by Yingjun Biotechnology Co., Ltd, China. An anti-CD137 rabbit mAb (#34549) used for IHC and IF and was purchased Cell Signaling Technology (CST, USA). An anti-CD8 mouse antibody (#66868-1-Ig) for IHC and IF was purchased from the Proteintech group, China. MojoSort™ Magnet, MojoSort™ Human CD8 Nanobeads and MojoSort™ Human CD8 Cell Isolation Kit were purchased from BioLegend, USA. An NF-kB p65 rabbit mAb (#8242) for flow cytometry and IF was purchased from CST, USA. An anti-cytokeratin mouse mAb (#ab756) used for IHC was purchased from Abcam, England. A purified anti-human CD3 mAb (OKT3, #317326) for cell incubation and anti-CD45-PerCP (#368506), anti-CD3-FITC (#300406), anti-CD8-APC (#301014) and anti-CD137-APC (#309809) antibodies for flow cytometry were purchased from BioLegend, USA.

**IHC assay**

Fresh tissues for phenotypic assays or collected primary GC cells for functional assays to test separation purity were fixed, dehydrated and paraffin embedded. Paraffin sections were dewaxed and rehydrated using a routine protocol [22]. The cells underwent antigen repair, neutralization of endogenous catalases, serum blocking, incubation with anti-CD137 rabbit mAb antibody (1:100, CST, USA), anti-Foxp3 rabbit mAb antibody (1:100, CST, USA), anti-cytokeratin mouse mAb antibody (1:100, Abcam, USA) and anti-CD8 mouse antibody (1:100, Proteintech group, China) at 4 °C overnight. Cells were incubated with a secondary antibody, and DAB was used for color development. Cells were counterstained, neutral gum sealed and observed according to a standard immunohistochemical operation procedure. PBS was used as a negative control. The stained sections were scanned using Panoramic MIDI. Image J was used to count positively stained cells. Two senior pathologists independently confirmed the results.

**IF assay**

Paraffin sections of a specimen for phenotypic assays were dewaxed and sealed with 3% H2O2 for 10 min and heat-retrieved with 0.01 mmol/l citrate buffer (pH = 6.0) for 10 min at 95 °C. After natural cooling, the sections were blocked with goat serum (Beyotime Biotechnology, China) for 30 min and incubated with an anti-CD137 rabbit mAb (1:100, CST, USA) and anti-CD8 mouse mAb (1:100, Proteintech group, China) overnight in a water tank at 4 °C. After 1 h of rewarming, antigens were detected with an anti-rabbit IgG (H+L), F(ab’)2 Fragment (Alexa Fluor® 594 Conjugate) and anti-mouse IgG (H+L), F(ab’)2 Fragment (Alexa Fluor® 488 Conjugate) (both 1:500, CST, USA). The sections were incubated at

---

**Table 2 Characteristics of patients for functional data**

| Sex | GC(18) |
| --- | --- |
| Female | 7 |
| Male | 11 |
| Age (years)** | 65.2 ± 3.1 |
| Tumor size (cm) |  |
| < 5 | 6 |
| ≥ 5 | 12 |
| Smoking |  |
| Yes | 10 |
| No | 8 |
| Drinking alcohol |  |
| Yes | 9 |
| No | 9 |
| Tumor location |  |
| Proximal | 4 |
| Distal | 14 |
| Histopathology |  |
| Highly differentiated adenocarcinoma of GC | 5 |
| Poorly differentiated adenocarcinoma of GC | 13 |
| Lymph node metastasis |  |
| N0–1 | 12 |
| N2–3 | 6 |

GC gastric cancer

**Mean ± SD**
37 °C for 1 h, and DAPI was added. The sections were incubated in the dark for 5 min, sealed with 50% glycerol, and observed under a confocal microscope.

After slide preparation, cells for IF in NF-κB p65 nuclear translocation assay were fixed in 4% paraformaldehyde and penetrated using 0.5% Triton X-100 at room temperature for 20 min. The slides were blocked with goat serum (Beyotime Biotechnology, China) for 30 min and incubated with an anti-NF-κB p65 rabbit mAb (1:100, CST, USA) overnight in a water tank at 4 °C. After 1 h of rewarming, the primary antibodies were detected using an anti-rabbit IgG (H+L), F(ab’)2 Fragment (Alexa Fluor® 594 Conjugate) (1:500, CST, USA) for 1 h. DAPI was added, and the sections were incubated in the dark for 5 min. Stained sections were observed under a fluorescence microscope.

Isolation of TILs
Gastric cancerous tissues were cut into 1-mm-diameter pieces using ophthalmic surgical scissors, and the appropriate amount of tissue digestive solution containing 2 mg/ml type IV collagenase and 0.25 mg/ml hyaluronidase was added. The samples were transferred to a 15-ml centrifuge tube and digested in a shaker at 37 °C for 30 min. The cell suspension obtained from digestion was filtered with a 70-µm sieve, and the filtered liquid was collected in a 50-ml centrifuge tube. Ten milliliters of Ficoll lymphocyte separation solution was added to the bottom of 50-ml centrifuge tubes, and the tubes were centrifuged at 716g for 20 min for lymphocyte removal. Cells at the bottom of 50-ml centrifuge tubes were collected, and erythrocyte lysate was added for 10 min to remove red cells. The cells were washed with sterile PBS containing 1000 U/ml penicillin and streptomycin 5 times.

Isolation of PBMCs and CD8+ T cells
After transferring 20 ml of blood from patients with GC into 50-ml centrifuge tubes, 10 ml of PBS was added to dilute the blood. The solution was mixed gently, and 10 ml of Ficoll lymphocyte separation solution was added to the bottom of 50-ml centrifuge tubes. Samples were centrifuged at 716g for 20 min, and lymphocytes were collected and washed twice with PBS for 5 min each time. Isolated PBMCs were washed with MojoSort™ buffer once. The experimental procedure for CD8 isolation protocol was performed according to the MojoSort™ Human CD8 T Cell Isolation Kit provided by BioLegend, USA.

Isolation of primary GC cells
Fresh gastric cancerous tissues for functional assays were immersed in sterilized PBS containing 200 U/ml penicillin and streptomycin for 10 min, then washed with sterilized PBS containing 1000 U/ml penicillin and streptomycin 5 times. The specimens were immersed in sterilized PBS containing 200 U/ml penicillin and streptomycin for 10 min to remove blood and bacteria on the surface of the specimens. The tissue specimens were cut into 1-mm-diameter pieces using ophthalmic surgical scissors, and the appropriate amount of tissue digestive solution containing 2 mg/ml type IV collagenase and 0.25 mg/ml hyaluronidase was added. The samples were transferred to a 15-ml centrifuge tube and digested in a shaker at 37 °C for 30 min. The cell suspension obtained from digestion was filtered with a 70-µm sieve, and the filtered liquid was collected in a 50-ml centrifuge tube. Ten milliliters of Ficoll lymphocyte separation solution was added to the bottom of 50-ml centrifuge tubes, and the tubes were centrifuged at 716g for 20 min for lymphocyte removal. Cells at the bottom of 50-ml centrifuge tubes were collected, and erythrocyte lysate was added for 10 min to remove red cells. The cells were washed with sterile PBS containing 1000 U/ml penicillin and streptomycin 5 times.

Primary GC cells and CD8+ T cells stained with CFSE
Primary GC cells and CD8+ T cells were collected and washed with PBS 3 times for 5 min each wash. Primary GC cells were treated with 1 ml of 5 µM CFSE and cultured in a 37 °C CO2 incubator for 15 min. One ml of fetal bovine serum was added to stop the staining for 1 min, and the cells were washed twice with PBS.

Cell culture
CFSE-labeled CD8+ T cells, PBMCs or/and CFSE-labeled primary GC cells isolated from GC patients were added to 96-well plates coated with a purified anti-human CD3 antibody (BioLegend, USA) at 5 µg/ml overnight to upregulate CD137 expression and cultured in DMEM with 10% FBS (Hyclone, USA).

Flow cytometry
For CD137 detection, the PBMCs or TILs of GC patients were placed in flow tubes, and 5 µL each of an anti-CD45-PerCP antibody (BioLegend, USA), anti-CD3-FITC antibody (BioLegend, USA) and anti-CD137-APC antibody (BioLegend, USA) was added. The cells were incubated in the dark for 10 min and washed with PBS once. PBS (200 µL) was added for flow cytometry detection.

For examination of CD8+ T cells proliferation, CD8+ T cells of GC patients were placed in flow tubes and washed once with PBS. PBS (200 µL) was added for flow cytometry detection.

For NF-κB detection, CD8+ T cells from GC patients were treated with 10 µg/ml anti-CD137 mAb (BPS Bioscience, USA) for 72 h and placed in flow tubes. After washing once with PBS, a Fixation/Permeabilization Solution (BD Cytofix/Cytoperm™) was added at room temperature for 30 min. After washing once with PBS, an NF-κB p65 rabbit mAb (1:1000, CST, USA) was
added. The cells were incubated in the dark for 1 h and washed once with PBS. Five microliters of anti-rabbit IgG (H+L), F(ab’)2 Fragment (Alexa Fluor® 594 Conjugate) (1:500, CST, USA) was added, and the cells were incubated in the dark for 30 min. After washing once with PBS, 200 µL of PBS was added for flow cytometry detection.

Primary GC cell apoptosis detection using flow cytometry
PBMCs (1 × 10^5) and primary GC cells (2 × 10^4, CFSE stained) were mixed, placed in anti-human CD3 antibody-coated 96-well plates containing 200 µL of 10% FBS (Hyclone, USA) DMEM, and treated with 10 µg/ml anti-CD137 mAb (BPS Bioscience, USA). Apoptosis in the GC cells was detected using flow cytometry after 72 h.

Real-time quantitative PCR (real-time PCR)
Total RNA was extracted by TRIzol reagent (Invitrogen, USA) according to the manufacturer’s instruction, and cDNA was generated using a TaKaRa PrimeScript RT Reagent Kit (TaKaRa, Japan) according to manufacturer’s instructions. Quantitative real-time PCR was performed on ABI step-one plus (Applied Biosystems, USA) using the TB Green Premix Ex Taq (TaKaRa, Japan). Data were normalized to the expression of β-actin. Primer pairs used in this study are presented in Table 3.

Statistical analysis
Statistical analyses were performed using SPSS 26.0 software. The figures were plotted by GraphPad Prism 6 software. Continuous variables are shown as means±standard deviations (SD). Categorical variables were shown as counts and percentages. Descriptive statistics were shown as mean (standard deviations, SD) or median (interquartile range) according to data distribution. Statistical analyses between different groups were performed by one-way ANOVA, with S–N–K for post hoc multiple comparisons. An unpaired two-tailed Student’s t test was used for comparisons between two groups. Significant p-values are labeled with one or more ‘*’, denoting *p < 0.05, **p < 0.01, and ***p < 0.001. A threshold of P < 0.05 was defined as statistically significant.

Results
Poor infiltration of CD8^+ T cells but accumulation of Tregs in GCs
It is well known that CD8^+ T cells in gastric cancer tissues are favorable for prognosis of GC patients and Foxp3^+ Tregs are negatively associated with survival of GC patients. To compare the composition of CD8^+ and Treg cells in the tumor tissues, tumor-free tissues and tumor margin tissues of GC patients, we analyzed the proportions of CD8^+ and Foxp3^+ Tregs using IHC. Foxp3^+ Tregs accumulated in the tumor (Fig. 1a and b), but most CD8^+ T cells sequestered at the tumor margin and in tumor-free tissues (Fig. 1c and d). These data suggested that CD8^+ T cells were excluded from the tumors, and Foxp3^+ Tregs infiltrated into the tumors of GC patients.

CD137 was highly expressed in differentiated tumor and primarily expressed in CD8^+ T cells in GCs
Previous studies demonstrated that CD137 is mainly expressed in activated CD8^+ and CD4^+ T cells and Tregs [10, 11]. However, CD137 expression in GCs has not been investigated. TILs are important components in tumor immune microenvironment. To analyze CD137 expression in GCs, we first examined CD137 expression in TILs of GC patients. Notably, CD137 was highly expressed in differentiated tumor (Fig. 2a and b). This result was confirmed using IHC and IF (Fig. 2c and d).

| Table 3 Real-time PCR primers description |
|------------------------------------------|
| Gene          | Primer sequence       | Forward (5′-3′) | Reverse (5′-3′) |
|---------------|-----------------------|----------------|----------------|
| β-actin       | TGGCACCCAGCACAATGAA   | CTAAGTCTATGCTTGGCTAAGCA |
| IL-10         | GACCTTAAAGGTACCTGCGTGGTG | TCACATGGGGCTTGGATGTCTG |
| TGF-β         | ACTTGCACACCTTGGAGCTTC | GGTCTACACCTGGCTAAGCA |
| IFN-γ         | TCGGTTAAGAATTCATGCTC | TCGCTTCCCAGTATGCTG |
| Perforin      | CGGCCCATCAGGGCTATTC | CCTCAGCACTAGGCTAGTC |
| Granzyme B    | TGGGGGACCCAGAGATTAAAA | TTTGGCTCAATAGGAGCAATGCA |
IF showed that CD137 was primarily expressed in CD8+ TILs (Fig. 3a). Therefore, we focused on the function of CD137 on CD8+ T cells.

An agonistic anti-CD137 mAb enhanced CD8+ T cell proliferation and increased the secretion of IFN-γ, perforin and granzyme B, but had little effect on Tregs in GC

To determine the role of CD137 in the immune microenvironment of GC, CD8+ T cells were isolated from peripheral blood of GC patients (Fig. 3b–e) and stimulated with a CD137 agonist. The proliferation of CFSE-labeled CD8+ T cells was observed in the presence of an agonistic anti-CD137 mAb (Fig. 3f and g). We examined the overall effect of the CD137 agonist in GC patients. PBMCs were isolated from peripheral blood of GC patients. For Tregs, the secretion of IL-10 and TGF-β plays a role in maintaining immune tolerance. IL-10 and TGF-β were detected using real-time PCR. Our results showed that IL-10 and TGF-β levels were almost unchanged in the presence of a CD137 agonist (Fig. 4a and b). Notably, the CD137 agonist increased the production of IFN-γ, perforin and granzyme B (Fig. 4c–e) and secretion from CD8+ T cells in the PBMCs from GC patients. Taken together, these results demonstrated that the function of CD8+ T cells was enhanced in the presence of a CD137 agonist.

NF-κB expression and nuclear translocation increased in CD8+ T cells after CD137 agonist treatment

The NF-κB transcription factor is important in regulating cell division and proliferation. The activation of NF-κB signaling is mainly induced by nuclear translocation of
its subunits p65. After activation of NF-κB signaling, the levels and stability of the subunit p65 play an important role in the NF-κB signaling response. To examine the mechanism of CD137 in CD8$^+$ T cells, NF-κB subunit p65 expression and nuclear translocation were detected. Flow cytometry showed that p65 expression increased significantly in CD8$^+$ T cells in the presence of a CD137 agonist (Fig. 5a and b). Furthermore, IF showed that the CD137 agonist also induced p65 nuclear translocation in CD8$^+$ T cells (Fig. 5c).

A CD137 agonist induced apoptosis in primary GC cells
We investigated the effect of the CD137 agonist on primary GC cells. HE staining combined with IHC (cytokeratin antibody to confirm tumors) was used to examine the purity of primary GC cells after isolation (Fig. 6a–c). To further study the function of the CD137 agonist in the immune microenvironment of GC, we cocultured PBMCs and CFSE-labeled primary GC cells at a ratio of 5:1 in vitro in the presence of 10 µg/ml of the agonistic

![Fig. 2 CD137 expression in TILs of GCs.](image-url)

**Fig. 2** CD137 expression in TILs of GCs. **a** CD137 expression in GCs was examined using flow cytometry. **b** Statistical analysis of CD137 expression in different differentiations of GCs. **c** CD137 expression in GCs was measured using IHC and IF. **d** Statistical analysis of CD137 expression in different differentiations of GCs. Bars = mean ± SD. ***P < 0.001
anti-CD137 mAb. Flow cytometry was used to detect primary GC cell apoptosis after 72 h. Compared to control treatment, the CD137 agonist induced apoptosis in the primary GC cells (Fig. 6d and e).

**Discussion**

The morbidity and mortality of GC are high in the world, and the clinical therapeutic effect of monoclonal antibodies against a single target in GC is limited [6, 23, 24]. To improve the curative effect and reduce drug resistance, the identification of specific monoclonal antibodies for the treatment for GC is urgent [25, 26]. Immune escape is an important process of tumor development. We also found that the immunosuppressive microenvironment excluded CD8\(^+\) T cells from the tumors, but Foxp3\(^+\) Tregs infiltrated into the tumors of GC patients. CD137/CD137L targeted therapy is effective against melanoma, leukemia and other tumors [27]. The present study examined the effects of CD137 on the

---

**Fig. 3** CD137 was primarily expressed on CD8\(^+\) T cells and a CD137 agonist enhanced CD8\(^+\) T cell proliferation. a CD137 expression was examined using IF. b The ratio of CD8 in CD3 before isolation. c The ratio of CD8 in CD3 of an individual patient before isolation is presented. d The ratio of CD8 in CD3 after isolation. e Ratio of CD8 in CD3 of an individual patient after isolation is presented. f and g CD8\(^+\) T cell proliferation in response to a CD137 agonist. Bars = mean ± SD. ***P < 0.001
immune microenvironment of GC to provide new ideas for treatment.

We demonstrated that CD137/CD137L activation signaling promoted the activation and proliferation of tumor-specific T cells, increased the secretion of cytokines, and protected T cells from activation-induced cell death [28, 29]. The intraperitoneal administration of an anti-CD137 monoclonal antibody eliminated tumors that were established via subcutaneous inoculation of Agl04A sarcoma or 10815 mast cells in mice on the third and seventh day after inoculation, respectively [25]. The enhanced immune response was primarily mediated by CD8$^+$ T cells that were activated by the anti-CD137 monoclonal antibody and accompanied by a significant enhancement in tumor-specific cytotoxic T lymphocyte (CTLs) activity [30]. For CD4$^+$ T cells, CD137/CD137L signal transduction induces cell expansion but does not prolong cell survival [31]. CD137 is primarily expressed on the surface of activated T cells, and our study found that CD137 was predominantly expressed on the surface of CD8$^+$ T cells in the GC immune microenvironment and may positively correlate with tumor differentiation.

CD137 has a more restricted number of TRAF family members involved in its regulation, and only TRAF1,
TRAF2 and TRAF3 interact with and control CD137 activity [32]. Recruitment of the CD137 signalosome by K63-polyubiquitinated TRAF2 is a kinase complex composed of transforming growth factor beta-activated kinase (TAK)-1, which phosphorylates the inhibitor of nuclear factor κ-B kinase (IKK)-β and leads to the activation of canonical NF-κB [33]. Our results showed that a CD137 agonist enhanced CD8⁺ T cell proliferation.

Fig. 5 P65 expression and nuclear translocation were increased by the targeting of CD137. a, b The effect of a CD137 agonist on p65 expression was measured using flow cytometry. Bars = mean ± SD. ***P < 0.001. c The influence of a CD137 agonist on p65 translocation was detected using IF
A CD137 agonist also increased p65 expression and induced p65 nuclear translocation in CD8\(^+\) T cells, which suggests a mechanism for enhancing the functions of CD8\(^+\) T cells to induce gastric cancer cell apoptosis by a CD137 agonist.

Tregs plays a critical role in maintaining immune tolerance through IL-10 and TGF-β secretion [34]. CD8\(^+\) T cells are mounting to cancer responses by releasing perforin, granzyme B, and IFN-γ [35]. We examined the effects of a CD137 agonist on Tregs, and the results suggested that IL-10 and TGF-β levels were almost unchanged in the presence of a CD137 agonist. Interestingly, our study demonstrated that the CD137 agonist increased the secretion of IFN-γ, perforin and granzyme B in the CD8\(^+\) T cells. Furthermore, The CD137 agonist significantly induced apoptosis in cocultured primary PBMCs and primary GC cells, which suggests that a CD137 agonist is an adaptor in the immune microenvironment of GC (Fig. 7).
Conclusions

CD8⁺ T cells were excluded from tumors, and Foxp3⁺ Tregs infiltrated into the tumors in GC patients. CD137 was primarily expressed on CD8-positive T cells in the GC immune microenvironment. A CD137 agonist enhanced CD8⁺ T cells proliferation via NF-κB signaling and increased the secretion of IFN-γ, perforin and granzyme B but had little effect on Tregs in GC. A CD137 agonist induced apoptosis in primary GC cells. Our study provide the theoretical basis for the treatment of GC employing CD137 agonists.

Acknowledgements

Not applicable.

Authors' contributions

B-SH, H-MT and Y-ZX conceived the study and designed the experiments; B-SH performed in vitro experiments; TT, J-LJ and B-CX performed immunohistochemical staining and immunofluorescence; Y-YS and T-LW organized the clinical samples and analyzed the data; B-SH wrote the manuscript; H-MT modified the manuscript. All authors read and approved the final manuscript.

Funding

This study was supported by the Postgraduate Research & Practice Innovation Program of Jiangsu Province (KYCX19_1123), Wuxi City Health and Health Committee Youth Project (Q201919), Top Talents Project of the "Six-one Project" for High-level Health Talents in Jiangsu Province (LGY2018016), Application and Translation of Key Techniques on Gastrointestinal Lubricant (ZM008), and Key Talents Project of "Strengthening Health through Science and Education" of Wuxi Health and Family Planning Commission (ZDRC039). This study is also a Wuxi Science and Technology Development Medical and Health Guidance Plan.

Availability of data and materials

Data and materials are available for sharing if needed.

Ethics approval and consent to participate

This study has been conducted in accordance with ethical standards and according to the Declaration of the national and international guidelines, and has been approved by the authors’ institutional review board. The study protocol was approved by the Medical Ethics Committee of Jiangnan University (No. LS2018021).
Consent for publication
Written informed consent for publication was obtained from all participants.

Competing interests
The authors declare that they have no competing interests.

Author details
1 School of Basic Medical Sciences, Nanjing Medical University, 101 Long‑
mian Avenue, Jiangning District, Nanjing 211166, People’s Republic of China.
2 Department of Hepatobiliary Surgery, Affiliated Hospital of Jiangnan Uni‑
versity, Wuxi, People’s Republic of China.
3 Department of Pathology, Affiliated Hospital of Jiangnan University, Wuxi, People’s Republic of China.
4 Department of Gastroenterology, Affiliated Hospital of Jiangnan University, Wuxi, People’s Republic of China.
5 Department of Pathology, Affiliated Hospital of Jiangnan University, Wuxi, People’s Republic of China.

Received: 8 August 2020 Accepted: 12 October 2020
Published online: 20 October 2020

References
1. Coutzac C, Perrot S, Chaput N, Zaanan A. Immunotherapy in advanced
 gastric cancer, is it the future? Crit Rev Oncol Hematol. 2019;133:25–32.
2. Xu W, Yang Z, Lu N. Molecular targeted therapy for the treatment of
gastric cancer. J Exp Clin Cancer Res. 2016;35:1.
3. Abdul‑Latif M, Townsend K, Dearman C, Shiu K‑K, Khan K. Immunother‑
yapy in gastrointestinal cancer: the current scenario and future perspec‑
tives. Cancer Treat Rev. 2020;88:102030.
4. Tan S, Xia L, Yi R Han Y, Tang L, Pan Q, Tian Y, Rao S, Oyang L, Liang J, et al.
Exosomal miRNAs in tumor microenvironment. J Exp Clin Cancer Res. 2020;1:67.
5. Kang BW, Chau I. Current status and future potential of predictive bio‑
markers for immune checkpoint inhibitors in gastric cancer. ESMO Open.
2020;4:e000791.
6. Jones JO, Smyth EC. Gastroesophageal cancer: navigating the immune
and genetic terrain to improve clinical outcomes. Cancer Treat Rev. 2020;84:101950.
7. Wong HY, Schwarz H. CD137/CD137 ligand signalling regulates the
immune balance: a potential target for novel immunotherapy of auto‑
immune diseases. J Autoimmun. 2020;112:102499.
8. Kang SW, Lee SC, Park SH, Kim J, Kim HH, Lee H‑W, Seo SK, Kwon BS, Cho
HR, Kwon B. Anti‑CD137 suppresses tumor growth by blocking reverse
signaling by CD137 ligand. Cancer Res. 2017;21:5989–6000.
9. Cannons JL, Chamberlain G, Howson J, Smink LJ, Todd JA, Peterson LR,
Wicker LS, Watts TH. Genetic and functional association of the immune
signaling molecule 4‑1BB (CD137/TNFRSF9) with type 1 diabetes. J Auto‑
immun. 2005;1:13–20.
10. Lee S‑W, Vella AT, Kwon BS, Croft M. Enhanced CD4 T cell responsiveness
in the absence of 4‑1BB. J Immunol. 2005;17:6803–8.
11. Sabbagh L, Pellec G, Liu Y, Tisitskov EN, Watts TH. ERK‑dependent Bin
modulation downstream of the 4‑1BB‑TRA1 signaling axis is a critical
mediator of CD8 T cell survival in vivo. J Immunol. 2008;12:8093–101.
12. Sabbagh L, Andrevea D, Laramée GD, Oussa NAE, Lew D, Bisson N,
Sourmounou Y, Pavison T, Watts TH. Leukocyte‑specific protein 1 links TNF
receptor‑associated factor 1 to survival signaling downstream of 4‑1BB in
T cells. J Leukoc Biol. 2013;5:713–21.
13. Kotanides H, Sattler RM, Lebron MB, Carpenito C, Shen J, Li J, Surguladze
D, Hadar JN, Burns C, Shen L, et al. Characterization of 7AS: a human
CD137 (4‑1BB) receptor binding monoclonal antibody with differential
agonist properties that promotes antitumor immunity. Mol Cancer Ther.
2020;4:988–98.
14. Shedlock DJ, Whitmire JK, Tan J, MacDonald AS, Ahmed R, Shen H. Role of
CD4 T cell help and costimulation in CD8 T cell responses during Listeria
monocytogenes infection. J Immunol. 2003;4:2053‑63.
15. Li G, Wu X, Zhang F, Li X, Sun B, Yu Y, Yin A, Deng L, Yin J, Wang X. Triple
expression of B7‑1, B7‑2 and 4‑1BBL enhanced antitumor immune
response against mouse H22 hepatocellular carcinoma. J Cancer Res Clin
Oncol. 2011;4:695–703.
16. Serghides L, Bulczynski J, Jen T, Wang C, Routy J‑P, Boussell M‑R, Sekaly
R‑P, Ostrowski M, Bernard NF, Watts TH. Evaluation of CD40 ligand as a
costimulator of human antiviral memory CD8 T cell responses: compar‑
ison with B7‑1 and 4‑1BBL. J Immunol. 2005;10:6366–77.
17. Arron JR, Pwazer‑Jung Y, Walsh MC, Kobayashi T, Choi Y. Regulation of the
subcellular localization of tumor necrosis factor receptor‑associated factor
(TRAF2) by TRAF1 reveals mechanisms of TRAF2 signaling. J Exp
Med. 2002;7:923–34.
18. McPherson AJ, Snell LM, McK T, Watts TH. Opposing roles for TRAF1
in the alternative versus classical NF‑κB pathway in T cells. J Biol Chem.
2012;2:23010–9.
19. Freeman ZT, Nirschl TR, Hovelson DH, Johnston RJ, Engelhardt JH, Selby
MJ, Kochel CM, Lan YR, Zhai J, Chassagnezadeh A, et al. A conserved intratu‑
moral regulatory T cell signature identifies 4‑1BB as a pan‑cancer target. J
Clin Invest. 2020;3:1405–16.
20. Hodge G, Hodge S, Reynolds PN, Holmes M. Targeting peripheral blood
pro‑inflammatory CD28null T cells and natural killer‑like cells by inhibiting
CD137 expression: possible relevance to treatment of bronchiolitis
oblitersan syndrome. J Heart Lung Transplant. 2013;11:1081–9.
21. Smith SE, Hoelzinger DB, Dominguez AL, Van Snick J, Lustgarten J.
Signals through 4‑1BB inhibit T regulatory cells by blocking IL‑9 produc‑
tion enhancing antitumor responses. Cancer Immunol Immunother.
2011;1:1775–87.
22. Zhang G, Hao C, Lou Y, Xi W, Wang X, Wang Y, Qu Z, Guo C, Chen Y, Zhang
Y, et al. Tissue‑specific expression of TIPE2 provides insights into its func‑
tion. Mol Immunol. 2010;15:2435–42.
23. Xu J, Zhang Y, Jia R, Yue C, Chang L, Liu R, Zhang G, Zhao C, Zhang Y,
Chen C, et al. Anti‑PD‑1 Antibody SHR‑1210 Combined with Apatinib for
advanced hepatocellular carcinoma, gastric, or esophagogastrectomy cancer:
an open‑label, dose escalation and expansion study. Clin Cancer Res.
2019;2:515–23.
24. Rocken C. Molecular classification of gastric cancer. Expert Rev Mol Diagn.
2017;3:293–301.
25. Ju S‑A, Lee S‑C, Kwon T‑H, Heo S‑K, Park S‑M, Paek H‑N, Suh J‑H, Choi HR,
Kwon B, Kwoun BS, et al. Immunity to melanoma mediated by 4‑1BB is
associated with enhanced activity of tumour‑infiltrating lymphocytes.
Immunol Cell Biol. 2005;4:344–51.
26. Zhou G, Sprengers D, Mancham S, Erik S, Boor PPC, van Beek AA,
Doukas M, Noordam L, Campos Carrascosa L, de Ruiter V, et al. Reduction
of immunosuppressive tumor microenvironment in cholangiocarci‑
noma by ex vivo targeting immune checkpoint molecules. J Hepatol.
2019;4:753–62.
27. Sanchez‑Paeulete AR, Labiano S, Rodriguez‑Ruiz ME, Azpilikueta A,
Etcheverria I, Bolaños E, Lang V, Rodriguez V, Aparicio MA, Jure‑Kunkel
M, et al. Deciphering CD137 (4‑1BB) signaling in T‑cell costimulation
for translation into successful cancer immunotherapy. Eur J Immunol.
2016;3:513–22.
28. St Rose M‑C, Taylor RA, Bandyopadhyay S, Qui HZ, Hagymasi AT, Vella
AT, Adler AJ. CD134/CD137 dual costimulation‑elicited IFN‑γ maximizes
effector T‑cell function but limits Treg expansion. J Autoimmun. 2012;1:105–18.
29. Yang J, Park OJ, Lee YJ, Jung H‑M, Weo KM, Choi Y. The 4‑1BB ligand
and 4‑1BB expressed on osteoclast precursors enhance RANKL‑
induced osteoclastogenesis via b‑directional signaling. Eur J Immunol.
2008;6:1598–609.
30. Dubrot J, Palazón A, Alfaro C, Azpilikueta A, Ochoa MC, Rouzaud A,
Martínez‑Forero I, Teijeira A, Berraondo P, Le Bon A, et al. Intratumoral
injection of interferon‑α and systemic delivery of agonist anti‑CD137
monoclonal antibodies synergize for immunotherapy. Int J Cancer.
2011;1:105–18.
31. Woroniecka KI, Rhodin KE, Dechant C, Cui X, Chongsathidkiet P, Wilkinson
D, Waihol‑Polanja J, Sanchez‑Perez L, Fecci PE. 4‑1BB Agonism averts TIL
exhaustion and licenses PD‑1 blockade in glioblastoma and other intra‑
tracranial cancers. Clin Cancer Res. 2020;6:1349‑58.
32. Zapata JM, Perez-Chacon G, Carr-Baena P, Martinez-Forero I, Azpilikueta A, Otano I, Melero I. CD137 (4-1BB) signalosome: complexity is a matter of TRAFs. Front Immunol. 2018;9:2618.

33. Li G, Boucher JC, Kotani H, Park K, Zhang Y, Shrestha B, Wang X, Guan L, Beatty N, Abate-Daga D, et al. 4-1BB enhancement of CAR T function requires NF-κB and TRAFs. JCI Insight. 2018;3:e121322.

34. Chen J, Ye X, Pitmon E, Lu M, Wan J, Jellison ER, Adler AJ, Vella AT, Wang K. IL-17 inhibits CXCL9/10-mediated recruitment of CD8 cytotoxic T cells and regulatory T cells to colorectal tumors. J Immunother Cancer. 2019;1:324.

35. Hodge G, Barnawi J, Jurisevic C, Moffat D, Holmes M, Reynolds PN, Jensmann H, Hodge S. Lung cancer is associated with decreased expression of perforin, granzyme B and interferon (IFN)-γ by infiltrating lung tissue T cells, natural killer (NK) T-like and NK cells. Clin Exp Immunol. 2014;179–85.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.